1. Bekesi, J. G., Holland, J. F., Fleminger, R., Yates, J., Henderson, E. S.: Immunotherapeutic efficacy of neuraminidase treated allogenic myeloblasts in patients with acute myelocytic leukemia. In: Control of neoplasia by modulation of the immune mechanism. Chirigos, M. (ed.), pp. 573-592. New York: Raven Press 1977.
2. Bonmassar, E., Bonmassar, A., Vadlamudi, S., Goldin, A.: Immunological alteration of leukemic cells in vivo after treatment with antitumor drug. Proc. Natl. Acad. Sci. USA 66, 1089–1095 (1970).
3. Bonmassar, E., Bonmassar, A., Vadlamudi, S., Goldin, A.: Antigenic changes of L 1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide. Cancer Res. 32, 1446–1450 (1972).
4. Campanile, F., Houchens, D. P., Gaston, M., Goldin, A., Bonmassar, E.: Increased immunogenicity of two lymphoma lines following drug treatment in athymic (nude) mice. J. Natl. Cancer Inst. 55, 207–209 (1975).
5. Chirigos, M. A., Humphreys, S. R., Goldin, A.: Effectiveness of cytoxan against intracerebrally and subcutaneously inoculated mouse lymphoid leukemia L 1210. Cancer Res. 22, 187–195 (1962).